A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS
Publication
, Conference
Brown, D; Bacha, J; Wagner, L; Leggas, M; Kanekal, S; Lopez, L; Sankar, N
Published in: NEURO-ONCOLOGY
2020
Duke Scholars
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
2020
Volume
22
Start / End Page
60 / 60
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Brown, D., Bacha, J., Wagner, L., Leggas, M., Kanekal, S., Lopez, L., & Sankar, N. (2020). A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS. In NEURO-ONCOLOGY (Vol. 22, pp. 60–60).
Brown, Dennis, Jeffrey Bacha, Lars Wagner, Markos Leggas, Sarath Kanekal, Lorena Lopez, and Neil Sankar. “A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS.” In NEURO-ONCOLOGY, 22:60–60, 2020.
Brown D, Bacha J, Wagner L, Leggas M, Kanekal S, Lopez L, et al. A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS. In: NEURO-ONCOLOGY. 2020. p. 60–60.
Brown, Dennis, et al. “A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS.” NEURO-ONCOLOGY, vol. 22, 2020, pp. 60–60.
Brown D, Bacha J, Wagner L, Leggas M, Kanekal S, Lopez L, Sankar N. A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS. NEURO-ONCOLOGY. 2020. p. 60–60.
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
2020
Volume
22
Start / End Page
60 / 60
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences